When Pfizer CEO Albert Bourla asked his employees to compress years of vaccine development and manufacturing into months, he knew the first reaction would be resistance. Faced with a task that seemed ...

Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad.

Pfizer’s CEO, Albert Bourla, Ph.D., has yet to top the $33 million in compensation that he earned on the coattails of megablockbuster COVID-19 sales in 2022, but a $27.6 million pay package after a ...

SAN FRANCISCO, Jan 12 (Reuters) - Pfizer (PFE.N), opens new tab is preparing for a consumer market for obesity drugs on par with the booming business it saw after it launched erectile dysfunction drug ...

Pfizer/BioNTech plans to ask for authorization of a COVID-19 vaccine for some children under 12 soon, bringing the US one step closer to offering protection to a population that has grown particularly ...

Pfizer Inc. (NYSE: PFE) CEO Albert Bourla sharply criticized Robert F. Kennedy's views on vaccines, calling them "anti-science." He suggested that meaningful progress on immunization policy would ...

While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizer’s CEO ...

By Mariam Sunny March 2 (Reuters) - Pfizer CEO Albert Bourla said the company "has a problem" with the U.S. Food and Drug Administration's biologics and vaccines chief, Vinay Prasad, in response to a ...